PHOB 1429651-50-2

簡(jiǎn)要描述：PHOB 1429651-50-2
HPOB is a potent, selective HDAC6 inhibitor with IC50 of 56 nM, >30-fold selectivity over other HDACs.

產(chǎn)品咨詢聯(lián)系我們

產(chǎn)品分類

Product Category

查看全部

相關(guān)文章

詳細(xì)介紹

品牌	absin	CAS	1429651-50-2
分子式	C17H18N2O4	純度	＞98%
分子量	314.34	貨號(hào)	abs47028043
規(guī)格	5mg	供貨周期	現(xiàn)貨
主要用途	is a potent, selective HDAC6 inhibitor	應(yīng)用領(lǐng)域	化工,生物產(chǎn)業(yè),農(nóng)林牧漁,制藥/生物制藥,綜合

PHOB 1429651-50-2

產(chǎn)品描述
描述	HPOB is a potent, selective HDAC6 inhibitor with IC50 of 56 nM, >30-fold selectivity over other HDACs.
純度	＞98%
儲(chǔ)存/保存方法	Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution.
基本信息
外觀	white to beige powder
可溶性/溶解性	DMSO : 50 mg/mL (159.06 mM; Need ultrasonic)
生物活性
靶點(diǎn)	HDAC6,HDAC3,HDAC8,HDAC1,HDAC10
In vitro(體外研究)	In normal (HFS) and transformed (LNCaP, A549, and U87) cells, HPOB induces acetylation of α-tubulin, however, not histones, and inhibits cell growth, however, not viability. In HFS cells, HPOB enhances transformed cell death induced by etoposide, doxorubicin, or SAHA. HPOB also enhancing etoposide-induced transformed cell death via the apoptotic pathway in transformed cells.
In vivo(體內(nèi)研究)	In mice bearing CWR22 human prostate cancer xenografts, HPOB (300 mg/kg/d i.p.), when in combination with SAHA, causes suppression of the growth of established tumors, while produces no significant suppression when used alone.
參考文獻(xiàn)
參考文獻(xiàn)	1. Lee JH, et al. Proc Natl Acad Sci U S A. 2013, 110(39), 15704-157099.

研究領(lǐng)域
研究領(lǐng)域	EpigeneticsChromatin Modifying EnzymesAcetylation EpigeneticsChromatin Modifying EnzymesAcetylationHDACsClass II / Hda1 Class Stem CellsSignaling PathwaysWntHDACs Drug DiscoverySmall Molecule DrugLead Compound Discovery

PHOB 1429651-50-2溫馨提示：本產(chǎn)品僅作科研實(shí)驗(yàn)使用，不支持臨床等研究

產(chǎn)品咨詢